Home
>
US Stocks
>
VBI Vaccines Inc

VBI Vaccines Inc (VBIV)

$2.97

-0.05

(-1.66%)▲

Market is closed - opens 7 PM, 01 Jun 2023

Insights on VBI Vaccines Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 293.0K → 485.0K (in $), with an average increase of 39.6% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -21.14M → -37.42M (in $), with an average decrease of 77.0% per quarter

  • Vs SGEN

    In the last 1 year, Seagen Inc has given 45.9% return, outperforming this stock by 134.7%

  • Vs MRNA

    In the last 3 years, Moderna Inc has given 23.1% return, outperforming this stock by 118.1%

Performance

  • $2.88
    $2.99
    $2.97
    downward going graph

    3.03%

    Downside

    Day's Volatility :3.68%

    Upside

    0.67%

    downward going graph
  • $2.35
    $40.50
    $2.97
    downward going graph

    20.88%

    Downside

    52 Weeks Volatility :94.2%

    Upside

    92.67%

    downward going graph

Returns

PeriodVBI Vaccines IncSector (Health Care)Index (Russel 2000)
3 Months
-78.98%
0.7%
-6.8%
6 Months
-80.69%
-8.3%
-6.0%
1 Year
-88.79%
-1.9%
-4.6%
3 Years
-95.03%
25.3%
25.9%

Highlights

Market Capitalization
24.8M
Book Value
$5.23
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-14.43
PEG Ratio
0.0
Wall Street Target Price
4.0
Profit Margin
0.0%
Operating Margin TTM
-5927.07%
Return On Assets TTM
-33.11%
Return On Equity TTM
-137.24%
Revenue TTM
1.4M
Revenue Per Share TTM
0.17
Quarterly Revenue Growth YOY
284.90000000000003%
Gross Profit TTM
-10.2M
EBITDA
-83.3M
Diluted Eps TTM
-14.43
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-6.73
EPS Estimate Next Year
-2.53
EPS Estimate Current Quarter
-1.25
EPS Estimate Next Quarter
-1.14

Analyst Recommendation

Buy
    87%Buy
    12%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for VBI Vaccines Inc(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 34.68%

Current $2.97
Target $4.00

Company Financials

FY17Y/Y Change
Revenue
865.0K
↑ 57.85%
Net Income
-39.0M
↑ 68.05%
Net Profit Margin
-4.5K%
↓ 273.6%
FY18Y/Y Change
Revenue
3.4M
↑ 287.86%
Net Income
-63.6M
↑ 63.1%
Net Profit Margin
-1.9K%
↑ 2612.41%
FY19Y/Y Change
Revenue
2.2M
↓ 33.8%
Net Income
-54.8M
↓ 13.82%
Net Profit Margin
-2.5K%
↓ 572.26%
FY20Y/Y Change
Revenue
1.1M
↓ 52.23%
Net Income
-46.2M
↓ 15.66%
Net Profit Margin
-4.4K%
↓ 1889.27%
FY21Y/Y Change
Revenue
631.0K
↓ 40.53%
Net Income
-69.8M
↑ 50.88%
Net Profit Margin
-11.1K%
↓ 6697.15%
FY22Y/Y Change
Revenue
1.1M
↑ 71.47%
Net Income
-113.3M
↑ 62.43%
Net Profit Margin
-10.5K%
↑ 582.73%
Q4 FY21Q/Q Change
Revenue
81.0K
↓ 24.3%
Net Income
-18.8M
↑ 18.53%
Net Profit Margin
-23.2K%
↓ 8378.61%
Q1 FY22Q/Q Change
Revenue
126.0K
↑ 55.56%
Net Income
-21.3M
↑ 13.16%
Net Profit Margin
-16.9K%
↑ 6320.64%
Q2 FY22Q/Q Change
Revenue
346.0K
↑ 174.6%
Net Income
-45.7M
↑ 115.01%
Net Profit Margin
-13.2K%
↑ 3660.45%
Q3 FY22Q/Q Change
Revenue
317.0K
↓ 8.38%
Net Income
-25.2M
↓ 44.84%
Net Profit Margin
-8.0K%
↑ 5255.43%
Q4 FY22Q/Q Change
Revenue
293.0K
↓ 7.57%
Net Income
-21.1M
↓ 16.14%
Net Profit Margin
-7.2K%
↑ 737.01%
Q1 FY23Q/Q Change
Revenue
485.0K
↑ 65.53%
Net Income
-37.4M
↑ 77.01%
Net Profit Margin
-7.7K%
↓ 500.52%
FY17Y/Y Change
Total Assets
145.7M
↑ 39.05%
Total Liabilities
25.9M
↑ 23.05%
FY18Y/Y Change
Total Assets
137.6M
↓ 5.53%
Total Liabilities
39.5M
↑ 52.58%
FY19Y/Y Change
Total Assets
122.2M
↓ 11.19%
Total Liabilities
33.9M
↓ 14.0%
FY20Y/Y Change
Total Assets
209.4M
↑ 71.33%
Total Liabilities
37.7M
↑ 10.96%
FY21Y/Y Change
Total Assets
210.3M
↑ 0.43%
Total Liabilities
66.4M
↑ 76.27%
FY22Y/Y Change
Total Assets
155.1M
↓ 26.25%
Total Liabilities
90.9M
↑ 36.94%
Q4 FY21Q/Q Change
Total Assets
210.3M
↓ 6.22%
Total Liabilities
66.4M
↑ 3.6%
Q1 FY22Q/Q Change
Total Assets
194.0M
↓ 7.74%
Total Liabilities
64.4M
↓ 2.94%
Q2 FY22Q/Q Change
Total Assets
172.2M
↓ 11.26%
Total Liabilities
66.6M
↑ 3.35%
Q3 FY22Q/Q Change
Total Assets
172.0M
↓ 0.09%
Total Liabilities
88.2M
↑ 32.42%
Q4 FY22Q/Q Change
Total Assets
155.1M
↓ 9.84%
Total Liabilities
90.9M
↑ 3.1%
Q1 FY23Q/Q Change
Total Assets
128.5M
↓ 17.17%
Total Liabilities
83.4M
↓ 8.23%
FY17Y/Y Change
Operating Cash Flow
-31.4M
↑ 69.47%
Investing Cash Flow
-579.0K
↓ 138.6%
Financing Cash Flow
67.2M
↑ 84.3%
FY18Y/Y Change
Operating Cash Flow
-45.5M
↑ 45.1%
Investing Cash Flow
-6.0M
↑ 935.06%
Financing Cash Flow
43.6M
↓ 35.13%
FY19Y/Y Change
Operating Cash Flow
-48.7M
↑ 6.98%
Investing Cash Flow
-3.7M
↓ 38.71%
Financing Cash Flow
37.4M
↓ 14.22%
FY20Y/Y Change
Operating Cash Flow
-47.1M
↓ 3.41%
Investing Cash Flow
-26.0M
↑ 607.87%
Financing Cash Flow
122.4M
↑ 227.12%
FY21Y/Y Change
Operating Cash Flow
-39.9M
↓ 15.18%
Investing Cash Flow
23.2M
↓ 189.06%
Financing Cash Flow
44.3M
↓ 63.81%
Q4 FY21Q/Q Change
Operating Cash Flow
-18.5M
↑ 359.45%
Investing Cash Flow
-610.0K
↑ 43.53%
Financing Cash Flow
2.9M
↓ 59.01%
Q1 FY22Q/Q Change
Operating Cash Flow
-19.9M
↑ 7.61%
Investing Cash Flow
-515.0K
↓ 15.57%
Financing Cash Flow
12.0K
↓ 99.59%
Q2 FY22Q/Q Change
Operating Cash Flow
-17.5M
↓ 12.42%
Investing Cash Flow
-1.1M
↑ 109.13%
Financing Cash Flow
12.0
↓ 99.9%
Q3 FY22Q/Q Change
Operating Cash Flow
-17.3M
↓ 1.01%
Investing Cash Flow
-1.3M
↑ 20.71%
Financing Cash Flow
19.4M
↑ 1.619749E8%

Technicals Summary

Sell

Neutral

Buy

VBI Vaccines Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
VBI Vaccines Inc
VBI Vaccines Inc
2.06%
-80.69%
-88.79%
-95.03%
-96.79%
Moderna, Inc.
Moderna, Inc.
-4.27%
-29.63%
-10.94%
105.39%
586.61%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-8.82%
-3.37%
11.63%
22.7%
139.69%
Seagen, Inc.
Seagen, Inc.
-1.74%
61.71%
45.87%
23.07%
217.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-6.21%
0.88%
20.1%
12.88%
112.8%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
VBI Vaccines Inc
VBI Vaccines Inc
NA
NA
0.0
-6.73
-1.37
-0.33
0.0
5.23
Moderna, Inc.
Moderna, Inc.
11.46
11.46
0.0
-1.9
0.27
0.12
0.0
49.12
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
19.72
19.72
9.01
41.59
0.19
0.1
0.0
219.38
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-2.88
-0.23
-0.12
0.0
14.54
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.15
26.15
0.41
14.62
0.26
0.17
0.0
56.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
VBI Vaccines Inc
VBI Vaccines Inc
Buy
$24.8M
-96.79%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$49.1B
586.61%
11.46
31.77%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$79.5B
139.69%
19.72
33.81%
Seagen, Inc.
Seagen, Inc.
Hold
$36.7B
217.59%
NA
-31.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$83.8B
112.8%
26.15
35.4%

Institutional Holdings

  • Perceptive Advisors LLC

    20.26%

  • BlackRock Inc

    5.17%

  • State Street Corporation

    1.52%

  • Geode Capital Management, LLC

    1.51%

  • CAMBRIDGE Invest RESEARCH ADVISORS, INC.

    1.29%

  • Vanguard Group Inc

    1.03%

Corporate Announcements

  • VBI Vaccines Inc Earnings

    VBI Vaccines Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

VBI Vaccines Inc. is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI is advancing the prevention and treatment of hepatitis B, with: (1) the only 3-antigen hepatitis B vaccine, which is approved for use and commercially available in Israel under the name Sci-B-Vac® and completed its Phase 3 program in the U.S., Europe, and Canada in 2020; and (2) an immunotherapeutic in development for a functional cure for chronic hepatitis B. VBI's enveloped virus-like particle (eVLP) platform technology enables development of eVLPs that closely mimic the target virus to elicit a potent immune response. VBI's lead eVLP programs include a vaccine immunotherapeutic candidate targeting glioblastoma (GBM), a prophylactic cytomegalovirus (CMV) vaccine candidate, and a prophylactic coronavirus vaccine program. VBI is headquartered in Cambridge, MA, with research operations in Ottawa, Canada, and research and manufacturing facilities in Rehovot, Israel.

Organization
VBI Vaccines Inc
Employees
190
CEO
Mr. Jeffery R. Baxter F.C.M.A., FCMA
Industry
Health Technology

Discover More

FAQs